Kaleido Biosciences shares cratered, falling 76% in early trading Friday after the company disclosed in a regulatory filing that its board agreed to wind down and cease all operations—as part of which Kaleido will de-list its shares from The Nasdaq Stock Market. Kaleido has immediately terminated its top three executives: president and CEO Daniel Menichella, CFO William Duke, and chief scientific officer Johan van Hykckama Vlieg . . .
See More on the Edge
Continue reading this article and more
with a GEN Edge subscription
The post StockWatch: Kaleido Shares Crater as Company Ceases Operations appeared first on GEN – Genetic Engineering and Biotechnology News.
